Table 1 Comparison of the demographic and clinical findings of the oral BP and IV BP groups
Measurements | Oral BP Mean ± SD | IV BP Mean ± SD | Difference p value |
|---|---|---|---|
Number of patients | n = 251 | n = 27 | Â |
Age (years) | 73.2 ± 7.5 (min 40, max 90) | 64.1 ± 7.7 (min 51, max 80) | < .001 |
Sex (female, %) | n = 242 (96.4%) | n = 19 (70.4%) | < .001* |
Primary cause of BP medication | |||
 Osteoporosis | 251 | – |  |
 Malignant disease | – | 27 |  |
 Multiple myeloma | – | 15 |  |
 Breast cancer | – | 10 |  |
 Prostate cancer | – | 2 |  |
BP medication | |||
 Alendronate (weekly, oral) | 141 (56.2%) | – |  |
 Risedronate (weekly, or monthly, oral) | 47 (18.7%) | – |  |
 Ibandronate (monthly, oral) | 36 (14.3%) | – |  |
 Used multiple oral BP | 20 (8.0%) | – |  |
 Pamidronate (monthly, IV) | – | 1 (3.7%) |  |
 Zolendronate (monthly, IV) | – | 24 (88.9%) |  |
 Used multiple IV BP | – | 2 (7.4%) |  |
Duration of medication (months) | 53.1 ± 36.7 | 31.4 ± 20.4 | .003 |
MRONJ clinical stage | .079* | ||
 Stage 0 | 9 (3.6%) | 1 (3.7%) |  |
 Stage 1 | 6 (2.4%) | 2 (7.4%) |  |
 Stage 2 | 84 (33.5%) | 14 (51.9%) |  |
 Stage 3 | 152 (60.5%) | 10 (37.0%) | |